German biotech firm CureVac said its coronavirus vaccine showed just 48% efficacy against Covid-19 following its final analysis, marking only a slight improvement on the company’s last trial while sending its stock value tumbling. CureVac announced the second- and third-phase trial results for its CVnCoV vaccine on Wednesday, in its final analysis for a 40,000-subject study that drew participants from 10 countries across Europe and Latin America. “In the unprecedented context of 15 strains circulating within the study population at the time of final analysis, CVnCoV demonstrated an overall vaccine efficacy of 48%... against Covid-19 d
Hence then, the article about germany s curevac jab shows only 48 effectiveness against covid 19 in final stage of trial driving stock plunge was published today ( ) and is available onRussia Today ( News ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( Germany’s CureVac jab shows only 48% effectiveness against Covid-19 in final stage of trial, driving stock plunge )